Real-world study of an HIV treatment for people in difficult situations
Part of Infections clinical trials.
This study looks at how well a single-pill HIV treatment (BIC/FTC/TAF) works in real life for people in France who may have unstable housing or financial difficulties. It aims to understand if this treatment helps keep the virus under control in these situations.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older
- You have HIV-1
- You live in France and have C2S or AME health coverage
- You have never taken HIV treatment before, or you are switching to or already taking BIC/FTC/TAF
- You have had at least one follow-up doctor's visit after starting the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well women with HIV stay in care while taking the medication Biktarvy (a combination of three drugs in one pill). It aims to understand their health outcomes and support better care.
This study looks at where HIV hides in the body (called the viral reservoir) in men whose HIV is well controlled with Biktarvy. Researchers want to see how the levels of HIV medicines in the body relate to these hidden virus cells, which may help improve future treatments.
This trial provides continued access to Biktarvy (B/F/TAF) for children and adolescents who completed a previous Gilead HIV study. It ensures they can keep taking the medication without interruption.
This trial tests the medication Biktarvy (bictegravir, emtricitabine, and tenofovir alafenamide) for people with HIV who have stopped taking their antiretroviral therapy (ART) for at least 12 weeks and are ready to restart treatment. It aims to see how well the medication works when restarting care.
This study compares two HIV medications (DTG/3TC and BIC/TAF/FTC) to see which works better and is safer for people who have never taken HIV treatment before. It may help you find a once-daily pill that controls the virus and has fewer side effects.
This trial checks if the once-daily HIV pill Biktarvy (B/F/TAF) stays safe and works well for women who are newly pregnant (up to 12 weeks). It is for women already taking Biktarvy with a controlled virus load.
Hear when a new HIV-1 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.